How many types of cancer are being tested in RGCC’s “all types of cancer” tests?
These tests are for all solid and blood tumours malignancies, with the exception of primary tumours of the central nervous system.
Which tests can I use to diagnose and follow up men with an enlarged prostate who cannot have a biopsy?
We would recommend the Oncotrace test for diagnostic guidance, and the Prostate Oncotrail test for follow up focused on prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA) markers.
What do immunophenotype tests show?
The comparative genetic hybridisation (CGH) test provides information about genetic abnormalities present in tumour cells that can be associated with tumours. This test is relatively new and we do not yet provide it at RGCC.
Am I more likely to find the cause of a mutation if I combine both the ChemoSNiP for genomic DNA expression and the Onconomics test?
The Onconomics and Onconomics Plus tests provide information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.
ChemoSNiP tests for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs and other agents. This test cannot be used for gene expression analysis.
Is ChemoSNiP a blood test or a buccal swab? How do I collect the sample?
If you only need to order the ChemoSNiP test on its own, a swab is suitable. However if you wish to order other tests in addition to the ChemoSNiP, a patient’s DNA will be isolated from their blood. In this case, a blood sample is sufficient for both tests, so there is no need for a swab.
Does the ChemoSNiP test examine the cause of mutation?
The ChemoSNiP test provides information about DNA mutations that can affect how humans develop cancer or respond to anti-cancer drugs and treatments.
Which test focuses on the efficacy of therapeutic agents against an individual patient’s cancer?
The ChemoSNiP test can be used to predict whether a patient will have a good or bad response to a drug, or no response at all.
Can the Immune-Frame test tell if a patient’s immune system is suppressed as a result of cancer, or if a suppressed immune system caused the cancer?
The Immune-Frame test focuses on the status of a patient’s immune system, based on their cellular markers and the level of cytokine proteins in the test sample.
Which test focuses on the status of the immune system and immunity?
The Immune-Frame test focuses on the status of a patient’s immune system.
Which tests are recommended for follow up and patient monitoring?
Oncocount, Oncotrace or Oncotrail tests can be used to follow up and monitor specific types of tumours.
Which tests are recommended to identify active substances and drugs that work against a tumour?
We recommend the Onconomics or Onconomics Plus tests.
Which test is appropriate for gene expression?
The Onconomics and Onconomics Plus tests look for the expression of genes that are linked with the effect of specific drugs on the cancer cells in a single patient.